In vitro activity of BRL 36650, a new semisynthetic penicillin
- 1 June 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (6), 972-976
- https://doi.org/10.1128/aac.29.6.972
Abstract
BRL 36650 [sodium 6 beta-(D-2-[(4-ethyl-2, 3-dioxopiperazin-1-yl)carbonylamino]-2-(3,4-dihydroxyphenyl) acetamido)-6 alpha-formamido-penicillinate] is a new semisynthetic penicillin. It was tested in vitro for activity against 884 organisms cultured from blood specimens of cancer patients. BRL 36650 had broad-spectrum activity against the gram-negative bacilli tested but had no gram-positive activity. The MIC against 90% of the Pseudomonas aeruginosa isolates was 3.12 micrograms/ml. The activity of BRL 36650 was superior to that of piperacillin, comparable or slightly inferior to that of aztreonam and ceftazidime, and lower than that of imipenem and amifloxacin. BRL 36650 should prove useful for the management of gram-negative bacillary infections, including those caused by P. aeruginosa.This publication has 5 references indexed in Scilit:
- In vitro studies of BMY-28142, a new broad-spectrum cephalosporinAntimicrobial Agents and Chemotherapy, 1985
- Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopeniaAntimicrobial Agents and Chemotherapy, 1984
- In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillinAntimicrobial Agents and Chemotherapy, 1984
- Antibiotics in patients with neutropenia.1984
- Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infectionsAntimicrobial Agents and Chemotherapy, 1982